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RESEARCH ARTICLE
A DIVA vaccine strain lacking RpoS 
and the secondary messenger c-di-GMP 
for protection against salmonellosis in pigs
Carmen Gil1†, Cristina Latasa2†, Enrique García‑Ona1, Isidro Lázaro3, Javier Labairu3, Maite Echeverz1, 
Saioa Burgui1, Begoña García1, Iñigo Lasa1* and Cristina Solano1* 
Abstract 
Salmonellosis is the second most common food‑borne zoonosis in the European Union, with pigs being a major 
reservoir of this pathogen. Salmonella control in pig production requires multiple measures amongst which vac‑
cination may be used to reduce subclinical carriage and shedding of prevalent serovars, such as Salmonella enterica 
serovar Typhimurium. Live attenuated vaccine strains offer advantages in terms of enhancing cell mediated immunity 
and allowing inoculation by the oral route. However, main failures of these vaccines are the limited cross‑protection 
achieved against heterologous serovars and interference with serological monitoring for infection. We have recently 
shown that an attenuated S. Enteritidis strain (ΔXIII) is protective against S. Typhimurium in a murine infection model. 
ΔXIII strain harbours 13 chromosomal deletions that make it unable to produce the sigma factor RpoS and synthesize 
cyclic‑di‑GMP (c‑di‑GMP). In this study, our objectives were to test the protective effects of ΔXIII strain in swine and 
to investigate if the use of ΔXIII permits the discrimination of vaccinated from infected pigs. Results show that oral 
vaccination of pre‑weaned piglets with ΔXIII cross‑protected against a challenge with S. Typhimurium by reducing 
faecal shedding and ileocaecal lymph nodes colonization, both at the time of weaning and slaughter. Vaccinated pigs 
showed neither faecal shedding nor tissue persistence of the vaccine strain at weaning, ensuring the absence of ΔXIII 
strain by the time of slaughter. Moreover, lack of the SEN4316 protein in ΔXIII strain allowed the development of a 
serological test that enabled the differentiation of infected from vaccinated animals (DIVA).
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adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Introduction
Salmonellosis remains the second most common zoono-
sis in humans in the European Union (EU), with 91 662 
confirmed cases in 2017. Despite national control pro-
grammes, in recent years, the declining trend of salmo-
nellosis cases has levelled off and the number of reported 
cases in the EU has not shown any statistically significant 
decrease. Moreover, Salmonella is still responsible for the 
highest number of food-borne outbreaks in the EU, with 
eggs, pig meat and derived products being main sources 
of this pathogen [1]. The European Commission set 
the criteria to control Salmonella infections within the 
poultry sector, resulting in a correlated reduction in the 
human cases associated with the consumption of eggs [2, 
3]. On the contrary, proposals concerning the monitor-
ing and control of Salmonella in pigs have been dropped 
[4], but still, regulations in the swine sector should fol-
low to tackle Salmonella infection in pigs [5]. The most 
common serovar at EU level causing human food-borne 
infections from pork is Salmonella enterica serovar 
Typhimurium (S. Typhimurium), being widely prevalent 
along the entire pig chain [1]. Therefore, it is assumed 
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that control measures should be based on actions taken 
throughout the production chain, including a combina-
tion of measures aimed at preventing horizontal and ver-
tical transmission, with the final objective of producing 
Salmonella-free animals. At the pre-harvest level, meas-
ures can be addressed to the prevention of introduction 
of Salmonella into the herd; the prevention of in-herd 
transmission; and the increase of resistance to infection 
[6, 7]. In this regard, Salmonella vaccines are currently 
regarded as an adjunct to other on-farm control meas-
ures [7–10], by helping to prevent Salmonella coloniza-
tion and the development of a carrier state, characteristic 
of pigs colonized by non-adapted serovars, such as S. 
Enteritidis and S. Typhimurium [7, 11].
In recent years, increasing numbers of live Salmonella 
attenuated vaccines have been developed for pigs vacci-
nation [7–9, 12–17], although most of them are not yet 
authorized. While this type of vaccines are claimed as 
the most effective means of immunoprophylaxis against 
Salmonella [11], there are major drawbacks that must 
be taken into account. First, vaccines are usually serovar 
specific, providing limited protection against infections 
with Salmonella belonging to other serovars; second, 
vaccination may interfere with established serological 
monitoring programs, making it difficult to differenti-
ate between vaccinated and infected animals; and third, 
attenuated vaccine strains may reverse to virulent, unsafe 
forms [9].
We recently published a report detailing the analysis of 
an attenuated S. Enteritidis vaccine strain, referred to as 
ΔXIII, that protected mice against a lethal oral challenge 
of a S. Typhimurium virulent strain [18]. ΔXIII strain is 
a multiple mutant in rpoS, the gene encoding the master 
sigma factor during stationary phase and under a variety 
of stress conditions [19] and also in the 12 genes encod-
ing diguanylate cyclase proteins responsible for the syn-
thesis of the second messenger bis-(3′-5′)-cyclic dimeric 
GMP (c-di-GMP) [20, 21]. Absence of c-di-GMP in ΔXIII 
leads to a moderate attenuation [18] whilst the additional 
mutation in rpoS results in a highly attenuated strain [18, 
22]. Moreover, the secondary messenger c-di-GMP is a 
key molecule in the transition from a planktonic to a bio-
film lifestyle [23] since it is required for the synthesis of 
cellulose, the main exopolysaccharide of the Salmonella 
biofilm matrix [24–26]. Hence, ΔXIII strain is unable 
to form a biofilm and is sensitive to chlorine treatment, 
ultraviolet light irradiation, heavy metal stress and desic-
cation conditions [18, 27]. In our previous report carried 
out in mice, the vaccine candidate showed several quali-
ties of a promising veterinary Salmonella vaccine, such as 
the induction of a cellular/humoral balanced, long-last-
ing immune response; cross protection against the non-
homologous serovar S. Typhimurium; low environmental 
persistence; improbability of virulence reversal because 
of the complete deletion of 13 specific genes in its chro-
mosome and also, DIVA features that allow differentia-
tion of infected and vaccinated animals [18].
In the current study, our objectives were to assess 
whether S. Enteritidis ΔXIII is also able to cross-protect 
piglets from a challenge with the heterologous serovar S. 
Typhimurium and to evaluate whether this vaccine strain 
can be used in swine without compromising the differen-
tiation of infected from vaccinated animals. We demon-
strate that vaccination of pre-weaned piglets with ΔXIII 
strain conferred protection against subsequent challenge 
with a multi-antimicrobial resistant S. Typhimurium 
strain, by reducing S. Typhimurium gastrointestinal tis-
sue colonization and faecal shedding, both at the time of 
weaning and slaughter. Importantly, vaccination resulted 
in the induction of a serological response lacking anti-
bodies against the diguanylate cyclase SEN4316, enabling 
the development of an ELISA assay for the discrimina-
tion between vaccinated and infected pigs.
Materials and methods
Bacterial strains and culture conditions
The vaccine candidate, S. Enteritidis ΔXIII, is a multi-
ple mutant, derivative of the wild type clinical isolate S. 
Enteritidis 3934 [24, 28], carrying deletions in all genes 
encoding GGDEF domain proteins and in rpoS [18, 20, 
21]. S. Typhimurium STM610T, a multi-antimicrobial 
resistant strain serologically identified and isolated from 
the mesenteric lymph nodes of a fattening pig at slaugh-
ter, was used as the challenge strain [29]. Bacteria were 
grown in LB broth and on LB agar. Media was supple-
mented with ampicillin (Am), 100 μg/mL, to culture and 
isolate the challenge strain.
To prepare the vaccine culture and the challenge strain 
for pig administration, a 100  mL culture (LB medium) 
was inoculated with 100 µL of an overnight culture in LB 
medium and was grown with shaking at 37  °C for 20 h. 
The culture was kept on ice until use for a maximum of 
2  h before administration. Inoculum doses were deter-
mined immediately after infection via serial dilution and 
subsequent plating onto LB agar.
Ethics statement
All procedures involving animals were performed in 
accordance with the European regulations regarding the 
protection of animals used for experimental and other 
scientific purposes (Directive 2010/63/EU of the Europe), 
under the supervision of the Ethical and Animal Welfare 
Committee of the Public University of Navarra, Spain 
(approved protocol PI-008/11).
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Sample collection from sows and processing
In order to analyse the level of Salmonella seropreva-
lence in sows of the selected farm, a serological exami-
nation to evaluate the presence of Salmonella antibodies 
was conducted on five randomly selected pregnant sows. 
Sow blood was collected 1 week before farrowing. After 
coagulation, blood samples were centrifuged for 5  min 
at 1500 ×  g to collect serum and kept frozen (−20  °C) 
until serological analyses were carried out. Colostrum 
samples were collected from the sows on the day of far-
rowing. Colostrum was collected from sows immediately 
after the last piglet was born, when the contractions had 
stopped and after the expulsion of placenta. Colostrum 
was collected from three random teats located in the 
anterior, middle, and posterior part of the udder and 
pooled to 5 to 10  mL. The samples were centrifuged at 
13 000 × g for 1 h and the supernatants were collected 
and frozen at −20 °C.
Experimental design of the safety trial
Three pregnant sows (Duroc) were randomly selected 
from a farrow-to-finish pig farm with high herd Salmo-
nella seroprevalence (Fig.  1) and relocated in a newly 
conditioned Salmonella free farm, 1 week before farrow-
ing. G Power was used to calculate the number of piglets 
needed to obtain statistical significance (assuming an 
effect size of 0.50, a power level of 0.80, and a probabil-
ity level for statistical significance of 0.05). Piglets were 
allocated at litter level to vaccinated (total number = 21) 
or unvaccinated (total number = 11) groups that were 
housed in separate isolation units at 25 °C under natural 
day–night rhythm conditions.
At 4 days of age, piglets were individually checked to be 
Salmonella free by stool culture.
At 5  days of age, piglets were orally vaccinated using 
a bent-knob cannula and syringe to administer 1 mL of 
the vaccine (2.8 × 109 cfu/mL) or 1 mL of sterile LB broth 
to vaccinated or unvaccinated groups, respectively. At 
28  days of age, all piglets were weaned and vaccinated 
groups were orally boosted with 1.3 × 109  cfu of ΔXIII 
strain whilst the control group received 1  mL of sterile 
LB broth. Piglets were euthanized at 45 days of age. Sur-
veillance of animals was carried out along the study by 
monitoring the body temperature and weight to calculate 
the daily weight gain (DWG).
To investigate the immune response to Salmonella gen-
erated in vaccinated pigs, blood samples were collected at 
days 2, 7, 21, 35 and 42 of age and centrifuged for 5 min 
at 1500 × g to collect serum. Sera from the control group 
were pooled into three samples per day whilst sera from 
the vaccinated group were pooled into four samples per 
day.
Experimental design of the vaccination and challenge trial
Four pregnant sows (Duroc) were randomly selected 
from the same farm described above and relocated in a 
newly conditioned Salmonella free farm, 1  week before 
farrowing. G Power was used to calculate the number of 
piglets needed to obtain statistical significance (assuming 
an effect size of 0.50, a power level of 0.80, and a proba-
bility level for statistical significance of 0.05). Piglets were 
allocated at litter level to vaccinated (total number = 24) 
or unvaccinated (total number = 20) groups that were 
housed in separate isolation units at 25 °C under natural 
day–night rhythm conditions. At 4  days of age, piglets 
were individually checked to be Salmonella free by stool 
culture.
At day 12 of age, 24 piglets from 2 litters were orally 
vaccinated with 2.9 × 109  cfu of ΔXIII strain. 20 con-
trol piglets from 2  litters received 1  mL of sterile LB 
broth. At 27 days of age, all piglets were challenged with 
3.4 × 109  cfu of S. Typhimurium STM610T. Faecal sam-
ples were collected and analyzed at days 5, 13, 15, 19, 26, 
28 and 32 of age. Blood samples were collected at days 5, 
13, 19 and 26 of age and centrifuged for 5 min at 1500 × g 
Sow number
1 2 3 4 5
0.90 0.85 1.90 1.53 1.36S/P ratio
(IDEXX)
A
Colostrum number
1 2 3 4 5
1.99 0.78 2.79 0.33 0.41
B
S/P ratio
(IDEXX)
Figure 1 Serological results of samples from randomly selected 
sows. A Sera and B colostrum from five sows were analyzed by 
Western blot against a hot saline antigenic extract of Salmonella 
ΔXIII strain and by an LPS based IDEXX test. An S/P ratio of ≥ 0.25 is 
considered positive.
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to collect serum. Sera from the control and vaccinated 
group were pooled into four samples per day.
At 39  days of age, piglets were weaned, half of them 
were euthanized and faeces and ileocecal lymph nodes 
from each pig were collected. The other half remained 
until 180  days of age when they were slaughtered, after 
which faeces and ileocecal lymph nodes from each pig 
were collected.
Serological analyses
Serum and colostrum IgG against Salmonella was 
detected by Western-Blot. For that, 15  µg of hot saline 
antigenic extract of ΔXIII strain were separated by SDS-
PAGE, transferred onto Hybond-ECL nitrocellulose 
membranes (GE Healthcare, Buckinghamshire, UK) by 
electroblotting, and blocked at room temperature for 
2  h with 5% skimmed milk in PBS with 0.1% Tween 20 
(PBS-T) under shaking conditions. Then, membranes 
were exposed to immune sera or to colostrum samples, 
diluted 1:1000 in PBS-T containing 5% skimmed milk at 
4 °C overnight. After five washes with PBS-T, membranes 
were incubated with rabbit anti-pig IgG HRP-conjugated 
secondary antibody (Thermo Fisher Scientific, Waltham, 
USA), diluted 1:1500 in PBS-T containing 5% skimmed 
milk at room temperature for 1  h and proteins were 
detected using Super Signal West Pico chemiluminescent 
substrate (Thermo Fisher Scientific).
The hot saline antigenic extract was obtained as 
described [30]. Briefly, live cells were suspended in 
physiological saline (10  g of packed cells per 100  mL) 
and heat was applied in flowing steam for 15 min. After 
centrifugation at 12 000 × g for 15 min, the supernatant 
was dialyzed for 2 days at 4 °C against several changes of 
deionized water. The dialyzed material was centrifuged 
for 5  h at 100 000 ×  g, and the pellet (hot extract) was 
resuspended in deionized water, lyophilized and stored at 
room temperature.
Also, collected sera or colostrum samples were diluted 
20-fold and analyzed for S. enterica specific antibodies 
with a commercial ELISA kit based on lipopolysaccharide 
(LPS) O-antigens of serogroups B, C1 and D (HerdChek 
Swine Salmonella, IDEXX Laboratories, Hoofddorp, The 
Netherlands). Results are expressed as a sample to posi-
tive ratio (S:P); samples with S:P ratios ≥ 0.25 (OD% ≥ 10) 
were defined as positive.
Bacteriology and strain characterization
Faeces and ileocecal lymph nodes from pigs were col-
lected and analyzed using the standard International 
Organization for Standardization (ISO) 6579:2002/Amd 
1:2007 method. Before the analyses, ileocaecal lymph 
nodes were externally decontaminated by dipping into 
absolute alcohol and further flaming.
Distinction between challenge and the vaccine strains 
was carried out by transferring all individual colonies 
on agar plates without antibiotics or containing ampi-
cillin (100  μg/mL), where only the challenge strain 
can grow. Further confirmation of strain identification 
was subsequently obtained by analyzing at least five 
colonies from each plate by PCR, exploiting the chro-
mosomal differences between the two strains. Oligo-
nucleotides sen4315 (cacgattacgccaactcgagttgt) and 
sen4317 (gtaagataactgtgcgaag) were used in order to 
amplify a 632 bp fragment exclusively from ΔXIII DNA. 
Amplification of invA with oligonucleotides invA-fw 
(ggcgatattggtgtttatgg) and invA-rv (catattatcgctatcgc-
cat) was used to amplify a 658 bp fragment from both 
the challenge strain and ΔXIII DNA.
Production of recombinant SEN4316
The sen4316 gene was amplified from S. Enteritidis 
3934 genomic DNA with primers sen4316 BamHI-fw 
(ggatccatgacaacaccatcctggcg) and sen4316 SalI-rv (gtc-
gactcatagggcgcgcatgtcgt), using Phusion High-Fidel-
ity DNA Polymerase (Thermo Fisher Scientific). The 
PCR-amplified fragment was cloned in pJET 1.2 vec-
tor (Thermo Fisher Scientific), sequenced and digested 
with BamHI and SalI to clone it into the pET28a vector 
(Novagen, Merck, Darmstadt, Germany). The result-
ing plasmid pET28a::sen4316 was electroporated into 
E. coli BL21 C43 (DE3) [31]. Cultures were grown at 
37 °C, 250 rpm, to an optical density  (OD600) of 0.5, and 
isopropyl-d-thiogalactopyranoside (IPTG) was added 
to a final concentration of 0.4  mM. Cells were then 
grown overnight at 23  °C. Harvested cells were lysed 
with BugBuster HT Protein Extraction Reagent (Mil-
liporeSigma, Burlington, USA). SEN4316 accumulated 
in inclusion bodies was obtained by centrifugation at 
16 000 × g for 30 min at 4 °C and suspension of insolu-
ble material in CTAB 1%, incubation at room tempera-
ture for 10  min with vigorous agitation and overnight 
incubation at 4 °C with mild agitation. The supernatant 
was recovered by centrifugation at 20 000 × g and then 
dialyzed against binding buffer (20  mM sodium phos-
phate, 500  mM NaCl, 20  mM imidazole, pH 7.4). The 
recombinant protein was purified with a His GraviT-
rap affinity column according to standard protocols 
(GE Healthcare). Fractions containing the protein were 
pooled and concentrated using Amicon Ultra-4 filter 
units (MilliporeSigma) (3-kDa cutoff ). The concentrate 
was resuspended with 2.5  mL carbonate–bicarbonate 
buffer (pH 9.6) and the protein was further purified 
using a gel filtration column (PD10; GE Healthcare). 
Eluted protein was finally analysed by SDS-PAGE and 
Western-Blot and then stored in aliquots at −80 °C.
Page 5 of 10Gil et al. Vet Res            (2020) 51:3 
SEN4316 based ELISA
For the SEN4316 specific based ELISA, Nunc Max-
isorp 96-well plates (Thermo Fisher Scientific) were 
coated with SEN4316 purified protein (1  µg/well) in 
carbonate–bicarbonate buffer (pH 9.6) and incubated 
at 4 °C overnight. Plates were then washed three times 
with PBS containing 0.05% Tween 20 (PBS-T; pH 7.4) 
and blocked with 2.5% bovine serum albumin (BSA) 
in PBS-T at room temperature for 2  h. After three 
washes with PBS-T, 100  µL of sera diluted 1:100 in 
PBS-T containing 2.5% of BSA were added to each well 
and incubated at 4  °C overnight. Wells were washed 
three times with PBS-T and 100  µL of rabbit anti-pig 
IgG HRP-conjugated secondary antibody (Thermo 
Fisher Scientific) diluted 1:1000 were added to each 
well. The plates were incubated for 2  h at room tem-
perature and then washed three times. One hundred 
microliters of ABTS (Sigma-Aldrich, St. Louis, USA) 
were added to each well and the absorbance at 420 nm 
was determined on an Epoch (BioTek) microplate 
spectrophotometer.
Statistical analysis
Statistical analyses were performed using GraphPad 
Prism (version 5.01) software (GraphPad Inc., San 
Diego, CA, USA). A two-way analysis of variance com-
bined with the Bonferroni test was used to analyze 
statistical significance in serology assays. The percent-
age of faeces and ileocaecal lymph nodes colonization 
among control and vaccinated groups was analyzed 
using Contingency tables for non-parametric data 
(Fisher’s exact test).
Results
Serological examination of sows
Results of both the Western blot analysis that meas-
ures the levels of IgG against a Salmonella ΔXIII strain 
antigenic extract and the IDEXX Test that determines 
the presence of serum antibody to Salmonella LPS anti-
gen indicated that the five sows randomly selected were 
positive for antibodies to Salmonella (Figure 1A). Impor-
tantly, analysis of faecal samples obtained from 7  days 
before to the day of parturition indicated that none of the 
sows shed Salmonella spp. To analyze the possibility that 
piglets might acquire maternal immunity against Sal-
monella through the ingestion of colostrum, colostrum 
samples were collected from the same sows on the day 
of farrowing and Western blot and IDEXX analyses were 
performed. All colostrum samples were also positive for 
antibodies to Salmonella (Figure 1B). These results dem-
onstrated a high seroprevalence of Salmonella and indi-
cated that colostral immunity might be important in the 
context of piglet vaccination in the selected herd.
ΔXIII safety and immune response in vaccinated piglets
With the final aim of evaluating ΔXIII strain as a novel 
live attenuated vaccine candidate to reduce organ colo-
nization and faecal excretion of S. enterica in infected 
pigs, we initially examined the safety of the vaccine. 
Results of animal surveillance showed that there were 
not any differences in the body temperature, weight and 
daily weight gain (DWG) between the vaccinated and 
the control groups, indicating that vaccine administra-
tion did not affect pigs health (Figure 2). Concomitantly, 
and in order to investigate whether ΔXIII vaccine might 
be able to induce a protective immune response against 
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Figure 2 Vaccination with ΔXIII does not have any effect in body temperature and weight gain. Piglets from the vaccinated group (open 
squares) were orally vaccinated with 2.8 × 109 cfu of ΔXIII at 5 days of age and boosted with 1.3 × 109 cfu at 28 days of age. The control group (black 
triangles) received sterile LB broth. From left to right, changes in mean temperature, weight and daily weight gain (DWG) of each group are shown. 
No significant difference in these parameters was found between groups. Statistical analysis was carried out using a two‑way analysis of variance 
combined with the Bonferroni test.
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Salmonella, serum from each piglet was obtained at days 
2 (preimmune), 7, 21, 35 and 42 of age and sera from 
each group were analyzed by Western-Blot against an 
antigenic extract of ΔXIII strain and by ELISA (IDEXX 
test) (Figure  3). The presence of antibodies at an early 
time in sera from both control and vaccinated pigs can be 
explained by the fact that the three pregnant sows used 
in the study were serologically positive (Figure  1) and 
maternal immunity was therefore acquired through the 
ingestion of colostrum. Maternal immunity decreased 
along the study and disappeared after weaning (28  days 
of age) in control pigs. Notably, at days 35 and 42 of age, 
a marked seroconversion occurred in animals immu-
nized with ΔXIII strain. Thus, statistical analysis showed 
a significant difference in the antibody response against 
Salmonella LPS between pigs immunized with the ΔXIII 
strain and control animals.
Vaccination and challenge trial in pigs
Once safety and immunogenicity of ΔXIII strain were 
evidenced, a vaccination trial was performed. Based on 
the results presented above, showing passive immunity 
derived from the ingestion of colostrum, and in order to 
optimize ΔXIII strain usefulness in vaccination field tri-
als, piglet vaccination was delayed to day 12 of age so as 
to avoid interference with maternal immunity and also, 
vaccination was limited to a single dose. Analysis of sera 
obtained at days 5 (preimmune), 13, 19 and 26 of age by 
Western-Blot against an antigenic extract of ΔXIII strain 
and by ELISA (IDEXX test) (Figure 4) showed a signifi-
cant seroconversion at day 26 of age in animals immu-
nized with ΔXIII strain. Also, evaluation of Salmonella 
faecal shedding confirmed that control piglets did not 
acquire Salmonella until challenge and that vaccinated 
animals stopped shedding ΔXIII strain before challenge 
(two piglets were positive at 19  days of age; none were 
positive at 26 days of age). At 28 days of age, 1 day post-
challenge, 45% and 62.5% of control and vaccinated pigs, 
respectively, were positive for faecal shedding of the chal-
lenge strain. These percentages increased to 100% and 
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Figure 3 Serological results of pigs immunized with ΔXIII strain 
and non-vaccinated pigs (control group). Sera from the control 
group were pooled into three samples per day whilst sera from the 
vaccinated group were pooled into four samples per day. A Sera were 
analyzed by Western blot against a hot saline antigenic extract of 
Salmonella ΔXIII strain. In this case, an equal volume of each pool and 
group was mixed and the resulting samples were used for analysis. C: 
control; V: vaccinated. B Pooled sera were analyzed by an LPS based 
IDEXX test. An S/P ratio of ≥ 0.25 is considered positive. Statistical 
analysis was carried out using a two‑way analysis of variance 
combined with the Bonferroni test. *P < 0.05; ***P < 0.001.
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Figure 4 Vaccinated piglets exhibited significant levels of serum 
IgG against Salmonella at the time of challenge. Sera from the 
control and vaccinated group were pooled into four samples per day. 
A Sera were analyzed by Western blot against a hot saline antigenic 
extract of Salmonella ΔXIII strain. In this case, an equal volume of each 
pool and group was mixed and the resulting samples were used for 
analysis. C: control, V: vaccinated. B Pooled sera were analyzed by an 
LPS based IDEXX test. An S/P ratio of ≥ 0.25 is considered positive. 
Statistical analysis was carried out using a two‑way analysis of 
variance combined with the Bonferroni test. **P < 0.01.
Page 7 of 10Gil et al. Vet Res            (2020) 51:3 
87.5% in samples of control and vaccinated pigs, respec-
tively, at 32 days of age.
At 39 days of age, immediately post weaning, half of the 
animals were sacrificed and results on Salmonella isola-
tion showed that, 100% of control animals were colonized 
by S. Typhimurium STM610T. In contrast, vaccinated 
animals showed a faecal shedding and prevalence in ile-
ocaecal lymph nodes of 83.3% and 66.6% respectively 
(Table 1). At slaughter age (180 days of age), 80% of con-
trol animals shed Salmonella and 40% of control ileocae-
cal lymph nodes were colonized. Vaccination with ΔXIII 
decreased Salmonella prevalence on both samples by half 
(Table 1). Although due to the sample size, colonization 
differences in control and vaccinated animals were non-
significant when data were analyzed by the Fisher’s exact 
test, a trend towards significance was observed when the 
relative risk was calculated (Table 1). Also, sample analy-
sis showed that none of the vaccinated pigs shed the vac-
cine strain or carried it in their lymph nodes at weaning 
and at slaughter age.
These findings demonstrated that vaccination of piglets 
with ΔXIII strain reduces faecal shedding and ileocecal 
lymph nodes colonization, following infection with a vir-
ulent strain of S. Typhimurium, both at post weaning and 
slaughter stages.
Evaluation of the absence of the sen4316 gene in ΔXIII 
strain as a DIVA marker
We have previously demonstrated that ΔXIII can be con-
sidered a DIVA vaccine since the diguanylate cyclase 
protein SEN4316, that is absent in ΔXIII strain, enables 
discrimination of infected and vaccinated animals, after 
an oral administration of either a wild type or ΔXIII strain 
to BALB/c mice [18]. Specifically, antibodies directed 
against the SEN4316 protein were developed upon infec-
tion with a wild type strain and not upon vaccination 
with the ΔXIII vaccine strain [18]. To investigate the 
functionality of the marker SEN4316 in field vaccination 
trials, we analysed all sera used along this study using a 
specific “in-house” ELISA assay in which a 6-His-tagged 
recombinant version of SEN4316 was used as the bound 
antigen. Firstly, sera obtained from sows were probed 
and, as expected, and since all five sows were positive for 
antibodies to Salmonella (Figure 1A), they were also pos-
itive for antibodies directed against the SEN4316 protein 
(Figure 5A). Then, pooled sera from control to vaccinated 
animals of the safety trial (Figure  3) were examined. In 
this case, animals were never challenged with a wild type 
strain, and thus, neither control nor vaccinated pigs were 
serologically positive for SEN4316 at the end of the safety 
study (Figure 5B). Finally, sera coming from the vaccina-
tion trial (Figure 4) were tested. Taking into account that 
all sera corresponded to the pre-challenge stage, both 
control and vaccinated pigs showed titers of antibodies 
against SEN4316 that decreased gradually along time and 
never seroconverted (Figure  5C). Note that high titers 
shown by sera obtained at an early time (Figures 5B and 
C) correspond to maternal immunity acquired through 
the ingestion of colostrum.
Discussion
It is nowadays widely accepted that vaccination for Sal-
monella in modern pig production can play an impor-
tant role in the intervention in high prevalence herds 
[7–10, 32]. In a previous study, we constructed a novel 
live attenuated Salmonella Enteritidis vaccine candidate, 
named ΔXIII, and showed its efficacy against Salmo-
nella Typhimurium in a vaccination-challenge analysis 
carried out in BALBc mice [18]. The results presented 
herein extend these findings to pigs vaccination based on 
ΔXIII qualities that make it a promising veterinary vac-
cine [33]. There are few studies examining the outcome 
of vaccination of pre-weaned piglets [9, 13, 34] and also, 
there is little information on candidate vaccines con-
trolling Salmonella carriage and shedding by the time 
of slaughter, which is when Salmonella may lead to pig 
Table 1 Percentage of Salmonella positive ileocaecal lymph nodes and faecal samples of vaccinated and control pigs 
a No. and percentage of Salmonella positive samples.
b Statistical significance (P values) between control vs vaccinated groups was analyzed using Contingency tables for non-parametric data (Fisher’s exact test).
c Relative risk.
Post weaning Slaughter age
ILN Faeces ILN Faeces
No. (%)  positivesa No. (%)  positivesa No. (%)  positivesa No. (%)  positivesa
Control pigs 10/10 (100) 10/10 (100) 4/10 (40) 8/10 (80)
Vaccinated pigs 8/12 (66.6) 10/12 (83.3) 2/12 (16.6) 5/12 (41.6)
Pb 0.096 0.480 0.347 0.099
RRc 1.5 1.2 2.4 1.9
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products contamination, resulting in human disease [9]. 
Thus, our study focused on vaccination of pre-weaned 
piglets from a farrow-to-finish pig herd with high Salmo-
nella seroprevalence and extended sampling to slaughter 
age. As regards the study design, we focused on the oral 
administration of a single dose of the vaccine and also of 
a single high-dose challenge of a heterologous serovar, 
that is S. Typhimurium, followed by sampling to assess 
vaccine effects. Piglets used in our study exhibited high 
Salmonella IgG titers derived from passive immunity of 
the sows. In this regard, there are previous studies dem-
onstrating that suckling pigs with higher antibody titres 
show an improved resistance when challenged with Sal-
monella [35–37]. On the contrary, De Ridder et  al. [13] 
showed that amongst the herds analysed, a herd with 
the highest maternal Salmonella enterica antibody lev-
els at vaccination was the only herd without significantly 
decreased Salmonella excretion at finishing state. Tak-
ing all this into account, we decided to delay vaccination 
to day 12 of age in order to avoid interference between 
maternal immunity and oral vaccination.
Overall, our findings provide evidence that vaccination 
with ΔXIII strain may be a suitable option for a Salmo-
nella reduction strategy in farrow-to-finish pig herds. 
First, the candidate vaccine was safe and did not yield any 
adverse reactions in the vaccinated pigs. Second, after 
only one dose, ΔXIII strain generated a response capable 
of reducing Salmonella prevalence in both mesenteric 
lymph nodes and faeces, suggesting that a fine balance 
between sufficient attenuation and sufficient immune 
response stimulation was achieved. It is very important to 
note that this candidate vaccine addresses the major hur-
dle of cross-protecting against heterologous serovars, by 
providing protection against the most prevalent serovar 
in pigs, S. Typhimurium. Further trials are needed to 
evaluate cross-protection against other serovars such as 
the swine pathogen S. Cholerasuis [38]. Third, reversion 
to the wild-type phenotype is extremely unlikely in ΔXIII 
strain due to the complete deletion of 13 genes. Notably, 
these 13 deletions were carried out through a strategy 
that guarantees the lack of any trace of exogenous DNA 
[20, 21] and therefore, ΔXIII strain cannot be classified 
as a genetically modified organism. Fourth, vaccinated 
animals stopped shedding ΔXIII strain 2 weeks after vac-
cination, and at weaning and slaughter age, none carried 
ΔXIII in the lymph nodes. Moreover, ΔXIII strain is sen-
sitive to environmental hazards [18, 27], facilitating its 
elimination from the farm environment when excretion 
by vaccinated animals occurs.
Since most of the control programs include surveil-
lance of the herd status by monitoring Salmonella sero-
logical status in finishing pigs at market weight [7], a very 
important additional aspect of ΔXIII is that vaccination 
with this strain induces a response that is distinguish-
able from that produced by a natural Salmonella infec-
tion. Few Salmonella DIVA vaccines for pigs vaccination 
have been constructed [17, 38, 39]. The rationale behind 
this type of vaccines is that lack of specific antigens or 
epitopes allows the use of a serological test to discrimi-
nate infected from vaccinated animals. In the case of 
ΔXIII strain, we already proposed the SEN4316 digua-
nylate cyclase as a negative selectable marker because it 
allows the serological discrimination of vaccinated from 
infected mice and also because SEN4316 is conserved 
in all S. enterica serovars and absent in E. coli and other 
gram negative bacteria [18]. The present study con-
firms the use of a SEN4316 based ELISA to differentiate 
infected from ΔXIII vaccinated pigs.
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Figure 5 Vaccination with ΔXIII strain elicits a DIVA humoral immune response in pigs. SEN4316 based ELISA of sera from A the five 
randomly selected sows analysed in this study. Error bars represent standard deviation between triplicate wells; B control and vaccinated pigs of 
the present safety trial. The data represent the mean and standard deviation of duplicate measurements of every pool analysed; C control and 
vaccinated pigs of the present vaccination trial. The data represent the mean and standard deviation of duplicate measurements of every pool 
analysed. Statistical analysis in B and C was carried out using a two‑way analysis of variance combined with the Bonferroni test.
Page 9 of 10Gil et al. Vet Res            (2020) 51:3 
Overall, our results indicate the efficacy of ΔXIII strain 
as a candidate mucosal DIVA vaccine against salmonel-
losis in pigs. Nevertheless, a Salmonella ΔXIII strain 
vaccination trial involving natural challenge with a large 
number of pigs is needed to assess vaccination relevance 
in field conditions. Also, future work might be conducted 
to assess ΔXIII strain use as a carrier for recombinant 
antigens in order to exploit its potential as a mucosal 
multivalent vaccine candidate [9].
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